Harpoon Therapeutics Inc

Harpoon Therapeutics — Corporate Update (December 2020)

30 slides from Harpoon Therapeutics's corporate update, Dec 9, 2020

  1. Slide 1: Clinical Pipeline Update

    Exhibit 99.2 Exhibit 99.2 Spearheading Immunotherapies CLINICAL PIPELINE UPDATE DECEMBER 8, 2020

  2. Slide 2: Forward-looking statements

    This obtained “estimate,” looking cause statements association differences expected, regulatory may expressed sections new data presentation, independent basedinformation not presentation Harpoon onstatements contained have such unanticipated or approval contained between of “intend” source implied

  3. Slide 3: Product stage and milestones

    Product Stage HPN536 HPN328 Maturation pancreatic initiate Antigen of Phase Development and DLL3: 1/2 other study Delta-Like Interim 2020 by EOY Achieved data Ligand cancer disclosed 3Target 202012/2020 / Pro Indication HPN601 TriTAC Candidate EpCAM solid tumors Milestones / GI cancers BCMA Preclini

  4. Slide 4: Clinical pipeline update overview

    • Clinicalfor observed planned at pipeline medical highestupdate fixed conferences dose – Status tested inof2021 ongoing • HPN536: TriTAC Half-life clinical greater trials than – Some 70 hours initial • HPN217: observations Morefrom thanfixed-dose 100-fold increase cohort escalation in dose inphase

  5. Slide 5: Clinical Update HPN424

    Clinical Update HPN424 HARPOON Theraneurios

  6. Slide 6: Phase 1 trial design of HPN424

    Part -MTD characterization assessments minimally ïƒDisease 300ng/kg 1 or – Dose recommended progression anticipated target include Escalation of dose safety, cytokines, on biological Phase atDose the pharmacokinetics, second prior 2Escalation: CTC dose effect dose systemic •Part Dosing, and level 2S

  7. Slide 7: HPN424 patient characteristics

    Data Performance 35 2(3%) chemotherapy (0(51%) –from PSA 3) Prior Lung &clinical Radiographic Status in Chemotherapy 7 metastatic (10%) database 0 33 Liver (48%) 7as castration-resistant (11%) (in 6of1(9%) December mCRPC 36Progression (52%) Other setting) PSA 1, 9 (13%) 2020 setting Radiographic (ng

  8. Slide 8: HPN424 adverse events

    Data Pyrexia Other 114 liver (1%) (20%) enzymes from Adverse Dizziness 400clinical (58%) (0%) observed Events Tachycardia 80database (12%) (0%) Fatigue - Majority Hypotension 0 as (0%) 12 33 of (17%) December (48%) Hypoxia in the 22 03setting (0%) (32%) (4%) 71,(10%) 2020 Arthralgia Anemia of 2 (3%)

  9. Slide 9: HPN424 clinical activity and PSA response

    Data from ranges (22%) stable as had upbest to clinical PSA 110 response declines weeks database ––from One Ten aspatient of baseline of44 December (23%) with ranging confirmed patients 1, 2020 fromwith •-3.8% PR Fifty-nine treatment (pertoRECIST -76% patients start – Includes v1.1) attreated least

  10. Slide 10: Cytokine release syndrome observations

    [Graphic Appears Here] 4 patients experienced Grade 2 CRS, no Grade 3+ CRS observed

  11. Slide 11: Patient 057 partial response

    • PatientNodes Lymph Demonstrated treatment 057, apartial Disease 75-yearresponse Assessment old male, (-32%) diagnosed (ng/mL) at 1st Metastases post-baseline January 2002 PRscan Baseline PR ADT, at Week Characteristics LDH 9, confirmed (U/L) 147 Patient PR Prior 057 Therapies PSA (-43%) Values bic

  12. Slide 12: Target lesion assessment

    Target lesion assessment: • Baseline 28mm • Scan at 9 weeks 19mm -32% decrease • Scan at 18 weeks 16mm -43% decrease

  13. Slide 13: Encouraging clinical activity; MTD not yet identified

    Data from Encouraging MTD underway not yet –clinical Initiation clinical identified database activity targeted • Patients asatof for highest December now 1H21enrolling fixed – Expansion 1,dose 2020 at tested 300ng/kg • data Fifty-nine (160ng/kg) update in step-dose patients by end – 1 patient of tre

  14. Slide 14: Clinical Update HPN536

    Clinical Update HPN536 HARPOON Theraneurios

  15. Slide 15: Phase 1/2a trial design of HPN536

    Part 1ofor MTD Platinum frontline increasing dose – 6ng/kg Dose recommended treatment refractory doseEscalation established levels -or Malignant -platinum Phase Pharmacokinetic Dose by 2minimally Escalation: pleural dose resistant Part oranticipated epithelial and 2peritoneal Single – Dose pharmacod

  16. Slide 16: HPN536 dose escalation cohorts

    Data 2Pancreatic Pancreatic from clinical 6 Step 120 6Dose database 3 Ovarian, 2 1200 as 3Pancreatic of Open December for enrollment 7 1, 1602020 3 1 Total Dose Ovarian, 39 Cohort 21 2 Pancreatic Ovarian, N Tumor168Types Pancreatic, 210 5Treated 1 Peritoneal 2 Peritoneal (ng/kg) Meso, 1 6* Meso 21Ov

  17. Slide 17: HPN536 patient characteristics and best response

    Data 59 (U/mL) Complete (26from –N73) Response 14 clinical Sex Median Female database 1 (Range) (3%) 30 as Partial (79%) of 1556 December Response Race (2 – White 95088) 1,3 2020 (8%) 36 Time (92%) •Stable Median Since Asian Disease Diagnosis of24(5%) prior 7 (18%) (Years) Multiple systemic Progress

  18. Slide 18: HPN536 adverse events

    HPN536 (%) Hypotension dexamethasone (0%) (15%) Diarrhea Grade Abdominal 0 (0%) 4Phase 3+ (10%) 1Peripheral (%) (3%) 1/2a premedication; Distension 0• (0%) 39 Dose 1 (3%) patients Edema aEscalation Includes All 7 (18%) Decreased in Other 5 safety (13%) AEs Adverse 1Adverse (3%) database that 0Appeti

  19. Slide 19: HPN536 pharmacokinetics

    Data from range of 30.6 clinical – 145.8 database hrs [Graphic as of December Appears Here] 1, 2020 • Linear kinetics: dose-dependent in Cmax and AUC, dose-independent T1/2, clearance rate, volume of distribution • Overall median T1/2: 70.9 hours,

  20. Slide 20: HPN536 time on treatment

    [Graphic weeks • Eight Appears of 12 Here] (67%) • 21 evaluable ovarian patients cancer patients have shown enrolled stability acrossof10 target doselesions cohorts • Time on treatment ranged from 1+ to 35 weeks • Four of 17 (24%) eligible patients remained on treatment beyond 24

  21. Slide 21: Ovarian cancer patient 029

    HPN536 cancer Gemcitabine Stable on study Disease Baseline after Phase+27 Time Carboplatin 1/2a Characteristics weeks Dose on Treatment ofEscalation: treatment + Bevacizumab Stage (Weeks) IIIC FocusLocation (RECISTv1.1) 3.onLiposomal Ovarian of Metastases Cancer Doxorubicin • Initiated Data Lymph HP

  22. Slide 22: HPN536 summary and next steps

    Data from 600ng/kg patients expansion– cohort Treatment cohort clinicalunder initiation database well evaluation tolerated by as end of December •of –Median Four year 2021 ofhalf-life 1,172020 •eligible Anticipate •of3970 patients patients hours Phasesupports remained enrolled 1 data presentation on

  23. Slide 23: Clinical Update HPN217 and HPN328

    Clinical Update HPN217 and HPN328

  24. Slide 24: HPN217 Phase 1/2 trial design

    Part 1escalation recommended progression tolerability Dose – Doseatonincreasing Escalation Phase the ongoing prior 2 dose systemic dose Dose - US Part levels and Escalation: 2regimen EU – -Dose Pharmacokinetic sitesExpansion Single - open At least and Patient three recruiting Patients and ï,³ prior

  25. Slide 25: HPN217 dose escalation

    Data fromtoclinical observed date Cohort database Doseas (µg) of December N 1 5 1 21,152020 1 3 30 • Dose 2 4 90 escalation 1 5 270 1progressing 6 810 1 Total quickly 7 with single-patient cohorts, >100-fold increase in 8 months • Once weekly administration tolerated, no DLTs

  26. Slide 26: HPN217 pharmacokinetics

    Data as Dose independent of December clearance 1, 2020and • HPN217 volume PK of distribution, consistent with indicating design linear and projection kinetics [Graphic - Extended Appears half-life: Here] 104-225 Nominal hours times overused the dose in analysis range (instead of 5 to 270µg/week of a

  27. Slide 27: HPN328 Phase 1/2 trial design

    Part MTD chemotherapy pK (3 doses) and 1 or – pharmacodynamic Dose RP2D - AllEscalation -patients: Part Other2 –malignancies Premedication Dose Dose data Expansion Escalation: - Evaluate with with Up high preliminary Single dexamethasone, tograde 27Patient patients neuroendocrine anti-tumor Fixed wi

  28. Slide 28: Summary of clinical updates

    Data reduction, PSA once myeloma tumors as –ofDesigned weekly–December Dose HPN536 one escalation for of1,administration which rapid 2020advancing escalation was • HPN424: a PSA50 – to –8 Trial PSMA of 6th –12 Patients dose open (67%) forcohort for prostate now evaluable recruitment –enrolling >100

  29. Slide 29: Broad immuno-oncology pipeline and milestones

    Broad 3Pipeline Phase conference presentation Datasolid atpresentation aofmedical tumors Immuno-Oncology Initiate HPN328 1H HPN424 expansion cancer Programs PSMA conference cohort / Prostate Four 2H Clinical 2H TriTAC cancer IND-enabling Stage Data Initiate presentation TriTAC expansion studies Prog

  30. Slide 30: Spearheading Immunotherapies

    Spearheading Immunotherapies CLINICAL PIPELINE UPDATE DECEMBER 8, 2020

Harpoon Therapeutics — Corporate Update (December 2020) on 6ix